SRGN and neoplasm: Additionally, TTF1-negative LUAD cell lines often overexpress SRGN, encoding the proteoglycan serglycin, which promotes PD-L1 expression, proinflammatory cytokine production and increased tumour invasiveness and represents a potential therapeutic target [100].